HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support

Published:2004-07-26 Issue:5 Volume:34 Page:413-417
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Guarneri V,Bengala C,Orlandini C,Gennari A,Donati S,Campani D,Collecchi P,Maur M,Conte P F

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1704619.pdf

Reference34 articles.

1. Akiyama T, Sudo C, Ogawara H et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644–1646.

2. Stern DF, Heffernan PA, Weinberg RA . p185, a product of the neu proto-oncogene, is a receptor like protein associated with tyrosine kinase activity. Mol Cell Biol 1986; 6: 1729–1740.

3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182.

4. Ross JS, Fletcher JA . The HER/2neu oncogene: prognostic factor, predictive factor, and target for therapy. Semin Cancer Biol 1999; 9: 125–138.

5. Borg A, Baldetorp B, Ferno M et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994; 81: 137–144.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors for survival in metastatic breast cancer by hormone receptor status;Breast Cancer Research and Treatment;2014-04-26

2. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells;Life Sciences;2012-05

3. Prognostic Value of Initial Tumor Parameters After Metastatic Relapse;Cancer Investigation;2011-10-19

4. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status;Anti-Cancer Drugs;2009-11

5. Remote Optical Switch for Localized and Selective Control of Gene Interference;Nano Letters;2009-01-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3